CervoMed (CRVO)
Develops neflamapimod for age-related brain disorders.
$2.51
vs last close−0.02 (−0.79%)
Something off on this page? Send us feedback.
Next report
Nov 12, 26
estimated · in 50 days
EPS estimate
−$0.61
Revenue estimate
$50.0K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.80−$0.56−$0.70−$0.84−$0.88−$0.86−$0.64Pending
Estimate−$0.67−$0.60−$0.61−$0.68−$0.79−$0.90−$0.80−$0.61
Surprise−19.4%+6.7%−13.9%−23.5%−11.4%+4.4%+19.7%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$2.2M$1.9M$1.8M$322.6K$6.5K——Pending
Estimate$1.5M$1.7M$1.4M$1.2M$90.8K$71.4K$50.0K$50.0K
Surprise+40.8%+11.4%+26.8%−73.4%−92.8%———
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$0.10 | — | — |
| Sep 2028 | −$0.09 | — | — |
| Jun 2028 | −$0.08 | — | — |
| Mar 2028 | −$0.09 | — | — |
| Dec 2027 | −$0.49 | — | — |
| Sep 2027 | −$0.34 | — | — |
| Jun 2027 | −$0.29 | — | — |
| Mar 2027 | −$0.43 | — | — |
| Dec 2026 | −$0.45 | — | — |
| Nov 2026 | −$0.61 | — | — |
| Aug 2026 | −$0.80 | −$0.64 | +19.7% |
| May 2026 | −$0.90 | −$0.86 | +4.4% |
| Mar 2026 | −$0.79 | −$0.88 | −11.4% |
| Nov 2025 | −$0.68 | −$0.84 | −23.5% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Apr 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Nov 2022 | |||
| Sep 2022 | |||
| Aug 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$0.10 | — | — | $0 | — | — | — |
| Sep 2028 | −$0.09 | — | — | $0 | — | — | — |
| Jun 2028 | −$0.08 | — | — | $0 | — | — | — |
| Mar 2028 | −$0.09 | — | — | $0 | — | — | — |
| Dec 2027 | −$0.49 | — | — | $500.0K | — | — | — |
| Sep 2027 | −$0.34 | — | — | $325.0K | — | — | — |
| Jun 2027 | −$0.29 | — | — | $300.0K | — | — | — |
| Mar 2027 | −$0.43 | — | — | $333.3K | — | — | — |
| Dec 2026 | −$0.45 | — | — | $83.3K | — | — | — |
| Nov 12, 2026 | −$0.61 | — | — | $50.0K | — | — | — |
| Aug 10, 2026 | −$0.80 | −$0.64 | +19.7% | $50.0K | — | — | −0.4% |
| May 18, 2026 | −$0.90 | −$0.86 | +4.4% | $71.4K | — | — | −11.6% |
| Mar 13, 2026 | −$0.79 | −$0.88 | −11.4% | $90.8K | $6.5K | −92.8% | −1.9% |
| Nov 7, 2025 | −$0.68 | −$0.84 | −23.5% | $1.2M | $322.6K | −73.4% | −5.1% |
| Aug 8, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 17, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 9, 2024 | |||||||
| May 14, 2024 | |||||||
| Apr 1, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 15, 2023 | |||||||
| Mar 24, 2023 | |||||||
| Dec 31, 2022 | |||||||
| Nov 14, 2022 | |||||||
| Sep 29, 2022 | |||||||
| Aug 11, 2022 | |||||||
| Mar 30, 2022 | |||||||
| Dec 30, 2021 | |||||||
| Sep 29, 2021 | |||||||
| Jun 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 30, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 30, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 30, 2016 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 |